Financials & Filings

OTCQB: INTI
PRICE:
Stock Info

This section of the Inhibitor Therapeutics InvestorRoom houses up to date financial reporting information and interactive tools to provide you with the resources you need to manipulate and understand our current financial standing. 

Please note:  All data in this section is provided by a 3rd party provider and may be delayed up to 20 minutes.  Inhibitor Therapeutics assumes no responsibility for the accuracy of this data and provides it for informational purposes only.

Beta(0.48)
Shares Outstanding171.8M
Average Volume (10 days)3.3K
Qtrly Dividend (Ann. Yield)-- (--)

Per Share Data

Earnings (TTM)$0.03
Sales (TTM)--
Book Value (MRQ)$0.05
Cash Flow (TTM)$0.06
Cash (MRQ)$0.06

Analyst Views

Current Mean RecommendationN/A
Strong Buy0
 
Buy0
 
Hold0
 
Underperform0
 
Sell0
 

Recent Insider Transactions

Debra Peattie
Director
580,646
Acquire
Dec 22, 2020
Virca Nicholas
Ceo/President
125,000
Acquire
Dec 22, 2020
Robert Martin
Director
754,839
Acquire
Dec 22, 2020
Watson W.
Director
1,306,452
Acquire
Dec 22, 2020
Garrison J. Hasara
Cfo And Treasurer
125,000
Acquire
Dec 22, 2020

Recent SEC Filings

Company Events
May 31, 2023
>= 5% Acquisition
May 23, 2023
SC 13D
May 23, 2023
New Insider
May 22, 2023
>= 5% Acquisition
May 18, 2023
Get Important News and Updates by Email
* Required Fields